Received Mar 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient took three doses of Vivotif with food; Case reference number US-BN-2024-002756 is a spontaneous case initially received from a physician via Med Communications (reference number: USBAV24-2943) on 07-Nov-2024 and concerns an 18-years-old female patient. The patient's medical history and concomitant medications were not provided. On 31-Oct-2024, the patient took first dose of Vivotif, (batch number: unknown; expiration date: unknown) unknown dose (capsule), orally for pre-travel. On 02-Nov-2024, the patient took second dose of Vivotif, (batch number: unknown; expiration date: unknown) unknown dose (capsule), orally. On 04-Nov-2024, the patient took third dose of Vivotif, (batch number: unknown; expiration date: unknown) unknown dose (capsule), orally. The patient took three doses of Vivotif with food and had one left (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241107-d25567 to US-BAVARIAN NORDIC A/S-US-BN-2024-002756, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: An 18-year-old female patient took three doses of Vivotif for pre-travel with food, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An 18-year-old female patient took three doses of Vivotif for pre-travel with food, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None